ATYR – atyr pharma, inc. (US:NASDAQ)

News

aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating [Seeking Alpha]
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com